$Moderna, Inc.(MRNA)$ In 2022, Moderna expects to make between $17 billion and $22 billion in revenue from Spikevax. That's vastly more than its trailing revenue of $11.8 billion, and the global market for coronavirus vaccines is still quite far from being saturated.